Last week, the Food & Drug Administration (FDA) approved Biogen’s Aducanumab, a potentially revolutionary Alzheimer’s treatment. While the approval represents one of the first landmarks in the quest to improve outcomes for Alzheimer’s patients, the news wasn’t without...